Hosted on MSN1mon
Rodman & Renshaw sets Talphera stock Buy rating, $4 targetfor a Prior Approval Supplement (PAS) to amend its NEPHRO CRRT clinical study. The review aims to reduce the number of patients required for the study, which evaluates Niyad™, an anticoagulant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback